Barclays reiterates Eli Lilly stock Overweight on acquisition
📚 Related People & Topics
Eli Lilly
American pharmacist, Union Army officer, businessman, philanthropist (1838–1898)
Eli Lilly (July 8, 1838 – June 6, 1898) was an American Union Army officer, pharmacist, chemist, and businessman who founded Eli Lilly and Company. Lilly enlisted in the Union Army during the American Civil War and recruited a company of men to serve with him in the 18th Independent Battery Indiana ...
Entity Intersection Graph
Connections for Eli Lilly:
🏢
Food and Drug Administration
12 shared
🌐
Tirzepatide
7 shared
🏢
Novo Nordisk
5 shared
🌐
Ixekizumab
3 shared
🌐
Psoriasis
2 shared
Mentioned Entities
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Trump urges countries to "take" Hormuz as White House reportedly mulls Iran exit Gold prices set for bruising March losses amid Iran war Analyst trims S&P target, says stocks now pricing in bigger risk from war than oil Are defense stocks missing out on war-driven gains? Bernstein explains (South Africa Philippines Nigeria) Barclays reiterates Eli Lilly stock Overweight on acquisition By Analyst Ratings Published 03/31/2026, 01:21 PM Barclays reiterates Eli Lilly stock Overweight on acquisition 0 LLY 3.35% CNTA 44.58% 3696 -4.60% Investing.com - Barclays reiterated an Overweight rating and $1,350 price target on Eli Lilly stock (NYSE:LLY) following the company’s acquisition announcement. The pharmaceutical giant, with a market capitalization of $820 billion, has seen its shares decline 17% year-to-date despite strong revenue growth of 45% over the last twelve months. Eli Lilly announced the acquisition of Centessa Pharmaceuticals for total consideration of approximately $7.8 billion, consisting of $6.3 billion upfront and contingent value rights worth up to $1.5 billion. Centessa’s lead asset cleminorexton (ORX750) is an orexin receptor 2 agonist in development for sleep-wake disorders including narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia. Bloomberg consensus forecasts approximately $2.5 billion in sales by 2035 for these assets. Barclays views the deal as a tuck-in for Eli Lilly’s Neuroscience division. The company is expanding its pipeline outside neurodegenerative indications, including brenipatide currently in Phase 3 trials for alcohol use disorder and major depressive disorder. Eli Lilly faces an upcoming orforglipron PDUFA date on April 10. Centessa’s pipeline includes additional orexin receptor 2 agonists. For deeper insights into Eli Lilly’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro along with ...
Read full article at source